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The caspase-3 zymogen has essentially zero activity until it
is cleaved by initiator caspases during apoptosis. However,
a mutation of V266E in the dimer interface activates the
protease in the absence of chain cleavage. We show that
low concentrations of the pseudo-activated procaspase-3 kill
mammalian cells rapidly and, importantly, this protein is not
cleaved nor is it inhibited efﬁciently by the endogenous regulator
XIAP (X-linked inhibitor of apoptosis). The 1.63 Å (1 Å =
0.1 nm) structure of the variant demonstrates that the mutation
is accommodated at the dimer interface to generate an enzyme
with substantially the same activity and speciﬁcity as wild-
type caspase-3. Structural modelling predicts that the interface
mutationpreventstheintersubunitlinkerfrombindinginthedimer
interface, allowing the active sites to form in the procaspase in
the absence of cleavage. The direct activation of procaspase-3
through a conformational switch rather than by chain cleavage
may lead to novel therapeutic strategies for inducing cell
death.
Key words: apoptosis, cancer therapy, conformational switch,
co-operative dimer interface, procaspase activation.
INTRODUCTION
Caspase activation, more than any other event, deﬁnes a
cellular response to apoptosis. Synthesized initially as zymogens
(procaspases)(Figure1A),thecytosolicpoolofinactivezymogen
is converted rapidly into active protease upon the induction
of apoptosis. A fundamental difference exists in the caspase
subfamilies regarding maturation, and this difference is a
key aspect for regulating apoptosis. Initiator procaspases are
stable monomers in the cell, and dimerization is facilitated
following recruitment to activation platforms [1]. Importantly,
once dimerized, the initiator procaspases have high enzymatic
activity, and subsequent chain cleavage simply stabilizes
the active site [2,3]. In contrast, the effector procaspase-3 is a
stable dimer, but has very low enzymatic activity (< 0.4% of
that of the active protease) [4,5]. In this case, full activation
occurs after cleavage of the IL (intersubunit linker) by initiator
caspases, resulting in ordering of the active sites due to the
release of two active site loops (L2 and L2
 ) from the IL and
subsequent formation of the substrate-binding pocket (active
site loop 3) (Figure 1B, and see Supplementary Movie S1
at http://www.BiochemJ.org/bj/424/0335/bj4240335add.htm). In
short, the cell maintains a cytosolic pool of inactive procaspase-3
that is poised to carry out cell death.
Structural and mutational studies show that the packing of
amino acid side chains in the dimer interface is intimately
connected to active site formation (reviewed in [6–9]). The
importance of the dimer interface was described by Wells and
co-workers,whoshowedthatallostericinhibitorsbindintheinter-
face of the mature caspase and stabilize a form of the protein with
a disorganized active site, similar to that of the procaspase [10].
In addition to small molecule binding, mutations in the
allosteric site of the dimer interface were shown to affect active
siteformationinprocaspase-3[11].Inonecase,aV266Emutation
increasedtheactivityby60-fold,representingapseudo-activation
of the zymogen. Notably, the increase in activity did not require
cleavageofthe IL but rather occurredviaconformational changes
intheintactzymogen.Thisisanimportantconsideration,because
the results demonstrated that procaspase-3 can indeed gain a
substantial amount of catalytic activity without cleavage of the
polypeptide chain.
An understanding of procaspase dimerization and how it
relates to activation will be an important step toward effective
therapies for a variety of diseases that involve the dysregulation
of apoptosis. Although a number of cancer treatments target
proteins in the apoptotic pathways [12], most of the current
therapies are upstream of caspase activation and often require
combined treatments to be effective [13]. Ultimately, however,
these therapies indirectly induce the activation of caspase-3.
Because there is a larger pool of quiescent procaspase-3 in
most cancer cells compared with normal cells [14–16], directly
targeting procaspase-3 could lead to more effective therapy, since
effector caspases are the terminal proteases in the cell death
cascade. Overall, our results from the present study show that
the dimer interface should be considered a potential target for
cancer treatment, where the identiﬁcation of small molecules that
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Figure 1 Procaspase-3(D3A,V266E) is enzymatically active without cleavage of the IL
(A) The interface mutation V266E was designed in the context of wild-type caspase-3 (WT) and the uncleavable procaspase-3(D9A,D28A,D175A), called D3A. Low expression generates ‘one-chain’
procaspase-3 (Pro-WT). Overexpression generates the ‘two-chain’ caspase-3 (WT or V266E) by automaturation. ‘Pro’ refers to the pro-domain. (B) Structure of WT caspase-3 (PDB code 2J30)
highlighting the active site loops L1 (yellow), L2 (red), L3 (blue), L4 (brown) and L2  (cyan). The prime ( ) indicates residues from the second monomer. For clarity, only one active site is labelled.
(C)LabellingtheV266Emutantsbyafﬁnity-basedprobes.ProteinslabelledwithbEVD-AOMKwereprobedbyWesternblotanalysiswithanti-biotin,anti-cleavedcaspase-3,anti-full-lengthcaspase-3
oranti-His-tagantibodies,orsubjectedtotrichloroaceticacidprecipitationandstainedwithCoomassieBlue.ThepositivecontrolwasWT,andthenegativecontrolwasPro-WT.Theasteriskindicates
a contaminating protein from E. coli expression. Molecular masses are shown to the left in kDa. (D) Determining the substrate speciﬁcity of the recombinant caspase-3 mutants. Activity of the
caspase-3 mutants (10nM) was measured using a tetrapeptide positional scanning library, with P1 ﬁxed as an aspartate residue and 7-amino-4-carbamoylmethylcoumarin as the ﬂuorophoregroup.
Hydrolysis rates are presented as a percentage of the maximum rate for each subset (P2, P3 and P4).
bind to the interface of procaspase-3, resulting in its activation,
may be a viable alternative to current therapies.
EXPERIMENTAL
Materials
Ac-DEVD-AFC (acetyl-Asp-Glu-Val-Asp-7-amino-4-triﬂuoro-
methylcoumarin) was prepared in the Salvesen laboratory,
bEVD-AOMK (biotinylhexanoyl-Asp-Glu-Val-acyloxymethane;
KMB01) was generously provided by Dr Matthew Bogyo
(Stanford Comprehensive Cancer Center, Stanford, CA, U.S.A.),
Z-VAD-FMK (benzyloxycarbonyl-Val-Ala-Asp-ﬂuoromethyl
ketone) was from Enzyme System Products, and Ac-DEVD-
CMK (acetyl-Asp-Glu-Val-Asp-chloromethyl ketone) was from
Calbiochem. Isopropyl β-D-thiogalactoside was from BioVectra.
Constructs
Plasmids expressing C-terminal His-tagged proteins (Figure 1A)
have beendescribed previously[11]. Thefollowing (pro)caspase-
3 mutants were cloned into pcDNA3 (Invitrogen) as
C-terminus FLAG-tag constructs: wild-type procaspase-3,
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procaspase-3(D9A,D28A,D175A), procaspase-3(V266E) and
procaspase-3(D9A,D28A,D175A,V266E). These constructs are
referred to as WT, D3A, V266E and ‘D3A,V266E’ respectively.
pcDNA3 containing the gene for Bax and pcDNA/myc-XIAP
(X-linked inhibitor of apoptosis) were gifts from Dr John Reed
(The Burnham Institute for Medical Research, La Jolla, CA,
U.S.A.).C-terminalHis-taggedcaspase-3mutantswereexpressed
and puriﬁed as described previously [11]. Full-length XIAP
(N-terminal His tag) [17] and baculovirus protein p35 [18] were
expressed and puriﬁed as described previously.
Labelling with afﬁnity-based probes
Proteins were diluted in buffer [50 mM Hepes, pH 7.8, 100 mM
NaCl and 1 mM DTT (dithiothreitol)] at 250 nM ﬁnal
concentration and incubated with bEVD-AOMK (2.5 μM) for
30 min at room temperature (∼25◦C) in a total volume of 500 μl.
Half the samples were immediately subjected to Western blot
analysis, and the other half were concentrated ten times by
precipitation with trichloroacetic acid (10%) and examined
by SDS/PAGE (8–18% gradient gel), followed by Coomassie
Blue staining.
Positional scanning libraries
Positional scanning substrate combinatorial libraries (P4,
P3 and P2 positions) were synthesized similarly to the
previously published methods [19–21], as summarized in the
Supplementary online data (at http://www.BiochemJ.org/bj/
424/bj4240335add.htm).
Cell culture and transfection
HEK-293A (human embryonic kidney-293A) cells were
cultivated in Dulbecco’s modiﬁed Eagle’s medium. Jurkat and
MCF-7 cells were cultivated in RPMI 1640 medium. The media
were supplemented with 10% heat-inactivated bovine serum
(IrvineScientiﬁc),2 mM L-glutamineandpenicillin/streptomycin
(Invitrogen). For transfection, the adherent cells, at 40–60%
conﬂuence, were grown either in 6- or 12-well plates and were
transfected using GeneJuice® (Novagen), as suggested by the
manufacturer, with 3 μl of transfectant reagent per 1.0–2.0 μgo f
total DNA in 0.1 ml of serum-free medium. The control or the
dilution vector for transfected DNA was pcDNA3. At 2 h post-
transfection, Z-VAD-FMK (100 μM) or DMSO was added to
the cultured cells. The ﬁnal concentration of DMSO was 0.2%.
Cells were treated and harvested after 12–24 h, as described in
the Figure legends. For ﬂow cytometry experiments, cells were
trypsinized on the plate, resuspended in the culture medium,
washed with PBS and stained with Annexin V-PE using the
Apoptosis Detection Kit (BioVision). Positive Annexin V-PE
cells were analysed by FACS on a Becton Dickinson FACSort.
Individual experiments were normalized by dividing each
sample by the highest value (by Annexin V-PE staining) and
multiplying by 100 to give ‘percentage maximum apoptosis’.
Statistical analysis was performed using the paired Student’s
t test with two-tailed distribution. Untreated duplicate samples
were processed for immunoblotting and caspase activity assays.
Preparation of cell lysates and caspase activity measurements
wereperformedassummarizedintheSupplementaryonlinedata.
Western blot analysis and antisera
Cell lysates, balanced for total protein concentration, were
examined by SDS/PAGE (8–18% polyacrylamide gradient gel).
Proteins were transferred on to a PVDF membrane, blocked with
5% (v/v) non-fat dried skimmed milk powder in TBS-T (20 mM
Tris/HCl, pH 7.4, 150 mM NaCl and 0.1% Tween 20) and
subjectedtoimmunoblottingovernightat4◦Cagainsttheprimary
antibodies [in TBS-T with 5% (v/v) non-fat dried skimmed
milk powder]. The blot was washed with TBS-T followed
by incubation for 1 h with the appropriate secondary antibody
(1:10000) dissolved in TBS-T. The detection was performed
using the femtomolar enhanced chemiluminessence kit from
Pharmacia. The primary antibodies were used at the following
dilutions: anti-FLAG (M2) 1:2000 (Sigma F3165); anti-PARP
[poly(ADP-ribose) polymerase] 1:3000 (Pharmingen 556362);
anti-cleaved PARP 1:1000 (Cell Signaling Technology #9541);
anti-cleaved caspase-3 1:10000 (Cell Signaling Technology
#9661); anti-full-length caspase-3 1:5000 (BD Transduction
Laboratories clone 19); anti-ICAD 1:6000 (Cell Sciences
PX024 and PX023); anti-Hsp-90 1:5000, anti-XIAP 1:2000 (BD
TransductionLaboratories);andanti-His1:1000(Qiagen34660).
For biotin detection, the blots were blocked in 2% (w/v) BSA (in
TBS-T) overnight at 4◦C, then avidin–horseradish peroxidase (e-
Bioscience; 18-4100-51) was added at 1:5000 dilution for 30 min
at room temperature. Blots were washed three times for 10 min
with TBS-T prior to ECL detection.
Crystallization and data collection
Crystals of caspase-3(V266E) were grown, and results were
collected as described previously [22], except that the
cryoprotectant consisted of 90% reservoir buffer and 10%
2-methyl-2,4-pentanediol (Hampton Research). Crystals were
grown in the presence of the Ac-DEVD-CMK inhibitor and
appearedwithin4days.Afulldatasetwascollectedtoaresolution
of 1.63 Å (1 Å=0.1 nm) at 100 K at the SER-CAT beamline
(Advanced Photon Source, Argonne, IL, U.S.A.). V266E
crystallized with the symmetry of the orthorhombic space group
I222 with one heterodimer in the asymmetric unit. The biological
dimer of heterodimers is generated through a 2-fold symmetry
axis. The structure of V266E was determined using molecular
replacementwiththepreviouslydeterminedstructureofcaspase-3
for initial phasing (PDB entry 2J30). The inhibitor and all
water molecules were removed from the initial model and
all B-factors for protein atoms were set to 20 A
3. Inhibitor
and water molecules were added in subsequent rounds of
reﬁnement performed with COOT [23] and CNS [24] and
were positioned based on 2Fo −Fc and Fo −Fc electron
density maps contoured at the 1σ and 3σ levels respectively.
Crystallographic data collection and reﬁnement statistics are
shown in Supplementary Table S1 (http://www.BiochemJ.org/
bj/424/bj4240335add.htm).Procaspase-3homologymodelswere
generated as summarized in the Supplementary online data. The
atomic co-ordinates and structure factors for caspase-3(V266E)
have been deposited in the PDB under accession code 3ITN.
RESULTS
Caspase-3(V266E) interface mutants are active before processing
The enzyme activity of D3A,V266E was determined previously
from the hydrolysis of a typical caspase ﬂuorogenic substrate,
Ac-DEVD-AFC [11]. In those studies, Western blot analysis
showed that the high enzyme activity of D3A,V266E could not be
explained by an alternately cleaved protein because the enzyme
activity was only ∼ 3–4-fold lower than that of the mature
caspase-3. We examined this further by reacting the mutants
with an active site probe developed for caspases, bEVD-AOMK,
which labels the catalytic cysteine contained in a competent
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active site. As shown in Figure 1(C, top panel), the probe
covalently labelled the large subunit of WT (positive control),
but not the intact single-chain wild-type procaspase-3 (negative
control). Importantly, single-chain (uncleaved) D3A,V266E was
labelled nearly as well as the large subunit of cleaved V266E
and WT. Because D3A,V266E was shown previously to have
enzymatic activity equal to that of the mature V266E [11],
these results clearly show that the V266E mutation allows
for activity of single chain caspase-3 in the absence of
cleavage in the IL, at least on small synthetic substrates.
Furthermore,theV266Emutationdoesnotchangetheoligomeric
properties of caspase-3 from high micromolar to picomolar
range of protein concentration (see Supplementary Figure S1 at
http://www.BiochemJ.org/bj/424/bj4240335add.htm) [11].
In order to determine whether the mutation changed the sub-
strate speciﬁcity of the enzyme, we tested the P2–P4 sites in the
V266E mutants using a positional scanning peptide library con-
taining an aspartate residue ﬁxed in the P1 position (Figure 1D).
The results show that there are no substantial differences between
the speciﬁcity of WT and the V266E mutants for the P2–P4
positions, where maximum activity was obtained for the tetra-
peptide sequence DEVD. Overall, the results show that the
substrate speciﬁcities of the V266E mutants are very similar to
that of wild-type caspase-3, and suggest that the active site of the
activated procaspase resembles that of the mature caspase.
V266E interface mutants kill mammalian cells more efﬁciently than
wild-type caspase-3
One predicts that expression of a constitutively active
procaspase-3 should kill cells efﬁciently; indeed this has been
shown previously for a circular permutation of the caspase that
mimics IL cleavage [25]. However, it was not clear whether the
∼ 3–4-fold lower activity of the V266E mutants compared with
fully active wild-type caspase-3 represented sufﬁcient activity for
celldeath.Toexaminethis,wetransientlytransfectedHEK-293A
cells with various caspase-3 mutants and monitored cell viability
byAnnexinVstaining(Figure2A).Interestingly,bothV266Eand
D3A,V266Emutantsresultedinrobustcelldeath(∼ 50%),which
exceededthatproducedbyWTandD3A(∼ 20%).Thelossincell
viability produced by the interface mutants was as pronounced as
thatproducedbyBax,acytotoxicproteinthatinitiatestheintrinsic
apoptotic pathway at the mitochondrial level (Figure 2A). In all
cases, the levels of apoptosis were decreased in the presence of
a caspase inhibitor, Z-VAD-FMK, suggesting that the increased
levels of cell death were dependent on caspase activity. When
protein production was monitored by Western blot analysis, only
the WT and D3A species were detected by their reactivity to anti-
FLAG antibodies (Figure 2B). Compared with the endogenous
protein, the levels of WT were approx. 5–10-fold higher in
transfected cells, as judged by the anti-caspase-3 immunoblot.
The interface mutants could not be detected even after prolonged
exposures of the FLAG immunoblots, after immunoblotting with
anti-cleaved caspase-3 antibodies or when the proteasome inhib-
itor MG132 was added (results not shown). Thus the full-length
procaspase-3 observed in the cells transfected with the interface
mutants(Figure2B,toppanel)representstheendogenousprotein.
Immunoblots using cell lysates prepared at earlier time points
post-transfection gave the same results (results not shown). How-
ever, RT–PCR (reverse transcription–PCR) reactions showed the
presence of mRNA for the caspase variants (Supplementary Fig-
ure S2 at http://www.BiochemJ.org/bj/424/bj4240335add.htm),
demonstrating that the genes were transcribed. The parsimonious
explanation for the lack of immunostaining of transfected V266E
Figure 2 V266E mutants kill cells more efﬁciently than does the wild-type
caspase-3
(A) HEK-293A cells were transiently transfected with FLAG-tagged caspase-3 DNA (or 50 ng
Bax/0.95μgemptyvector),andAnnexinV-positivecellswerequantiﬁedafter24h.Z-VAD-FMK
(100 μM) or DMSO was added to the cultures 2 h post-transfection. The values represent the
means for three independent experiments+ −S.D. (B) Western blots of the cellular lysates from
(A) against anti-full-length caspase-3 or anti-FLAG antibodies, for detection of the transfected
constructs, or anti-cleaved PARP. The lower panel shows the loading control of Hsp90.
variants is that cells expressing them die before sufﬁcient
protein can accumulate, suggesting a lethal nature of the
interface mutation. In support of this assertion, we replaced the
catalytic cysteine residue in the V266E variants with a serine
residue to remove activity. We ﬁnd that the inactive V266E
variants no longer support apoptosis (Supplementary Figure
S3A at http://www.BiochemJ.org/bj/424/bj4240335add.htm). In
addition, the proteins are observed by anti-FLAG antibody
staining, although the accumulation remains lower than that for
WT. These data show that the toxicity of the V266E variants
requires catalytic activity.
In order to show that the cell death mediated by the
interface mutants involved typical caspase substrates, we
examined the cleavage of the canonical substrate PARP
(Figure 2B). Cleaved PARP exits the nucleus and resides
in the cytosol, so we examined the presence of cleaved
PARP in mRIPA (for composition see the Supplementary
Experimental section)-soluble lysates. As expected, PARP
wascleavedinallcellsdisplayinghighAnnexinVstaining,andits
cleavage was suppressed by Z-VAD-FMK (Figure 2B). Cleaved
PARP appeared to be in higher amounts in cells transfected with
WT, which may indicate a higher degradation rate of cleaved
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PARP in cells transfected with the interface mutants or with
Bax. We note that this experiment does not intend to quantify
the amount of apoptosis, because the lysates were from cells
collapsed in very late apoptosis, during which the process of
protein degradation was advanced. The results in Figure 2(B)
show the amount of cytosolic-cleaved PARP that leaked out of
the nucleus at the speciﬁed time and had not been degraded yet by
the proteasome. Owing to the fact that cells transfected with WT
undergo very incipient apoptosis with no cleaved PARP degrada-
tion, the amount of cleaved PARP may seem higher in these cells
in comparison with the cells transfected with V266E variants.
However, in reality most of the PARP in the nucleus remained in-
tact in cells transfected with WT, but was completely cleaved and
removed from the nucleus in the V266E lysates. In addition, the
cytosoliclevelsofcleavedPARPweremuchlowerinthecatalytic-
allyinactiveC163S,V266Evariants(SupplementaryFigureS3B).
Overall,theresultsshowthattheconstitutivelyactivecaspase-3
interface mutants were more efﬁcient in killing transfected
cells in culture than was wild-type caspase-3. Furthermore,
the apoptotic activity of the V266E variants did not depend
on the endogenous pool of procaspase-3. We transfected
MCF7 cells, which lack endogenous caspase-3 [26], with
plasmids containing the interface mutants, and we measured
apoptosis by Annexin V staining (Supplementary Figure S4A at
http://www.BiochemJ.org/bj/424/bj4240335add.htm). Although
the transfection efﬁciency was lower than in the case of HEK-
293A cells (∼ 35% compared with ∼ 60% respectively), the
pattern of cell death observed in the HEK-293A cells (Figure
2A) was reproduced in the MCF7 cells. One should note that
Bax, the positive control, was less toxic in MCF7 cells than were
the interface mutants due to the lack of endogenous caspase-3,
the main effector caspase. In all cases, the number of apoptotic
cells diminished in the presence of the caspase inhibitor Z-VAD-
FMK.
Similarly, we could show that recombinant V266E cleaved
caspase substrates in the absence of caspase-3 when added to
crude cellular extracts. We examined hypotonic lysates from
Jurkat cells that were immunodepleted of the endogenous
caspase-3 and reconstituted with recombinant caspase-3 proteins.
The lysates were analysed by Western blotting for cleavage of
ICAD (Supplementary Figure S4B). We observed that ICAD was
cleaved efﬁciently by the active WT and V266E proteins, and it
remainedunprocesseduponadditionofthelessactiveprocaspase-
3. The cleavage of ICAD was judged by the disappearance of the
full-length protein for which the antibodies were developed.
The intrinsic activity of interface mutants in transfected cells is
lower than that of WT
We examined the threshold of caspase activity necessary to
produce cell death by correlating the amount of death in cell
culture with the total caspase activity in the corresponding
lysates. We used the tetrapeptide substrate Ac-DEVD-AFC,
which is cleaved primarily by effector caspases, to measure
caspase activity in HEK-293A lysates that had been prepared
from cells transfected with the interface mutants (same lysates as
in Figure 2). Surprisingly, the lysates containing WT showed
the highest DEVD-ase activity (Figure 3A). We expected
to correlate this high activity to a high percentage of cell
death in culture (see Figure 2A), which was not the case. In
contrast, the lysates containing transfected interface mutants
or Bax displayed less than 15% of the DEVD-ase activity
of the WT lysates (Figure 3A), despite the high amounts of
Annexin V-positive cells present in the cell culture (Figure
2A). Lysates prepared from cells transfected with WT displayed
Figure 3 Wild-type caspase-3 lysates display higher DEVD-ase activity
than those of V266E interface mutants
(A)Lysatesfromcellstransfectedfor24hwiththeindicatedplasmidswereassayedforenzymatic
activity. The values represent the means + − S.D. for three independent experiments. Values for
the mean percentage apoptotic death are from Figure 2(A). RFU, relative ﬂuorescence units.
(B) Caspase-3 mutants (300 pM) were incubated with XIAP at the indicated concentration
in XIAP assay buffer (see Supplementary Experimental section) for 30min at 37◦C, and the
remainingactivitywastestedagainstAc-DEVD-AFC(100μM).Theactivityrateswereplottedas
thepercentageofthemaximumvelocityintheabsenceoftheinhibitor.Thedatawereﬁttedtoan
equation describing the enzymatic activity in the presence of a reversible competitive inhibitor
(see Supplementary Experimental section), and results of the ﬁts are shown in Table 1.
high DEVD-ase activity as early as 12 h post-transfection, and
the activity increased over time (Supplementary Figure S5A at
http://www.BiochemJ.org/bj/424/bj4240335add.htm). However,
lysates prepared from cells transfected with V266E showed
modest DEVD-ase activity compared with WT for each time
considered, and the activity did not peak earlier than 24 h
(Supplementary Figure S5A). Because the rate of cell death
peaked as early as 16 h after transfection with V266E (results
not shown), the results suggest that the apoptotic cells may have
leaked the cytosolic caspase-3 [27]. In that case, DEVD-ase
activity should be observed in the cell culture medium. However,
when we measured caspase activity in the supernatant after
removing the cells by centrifugation, we found that indeed there
was DEVD-ase activity in the cellular medium (Supplementary
Figure S5B), but the ratio between the activity of V266E mutants
and the activity of WT reﬂected the ratio found in the lysates
(Figure 3A). Therefore, the ‘missing’ DEVD-ase activity was not
in the cellular medium.
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Table 1 XIAP inhibition constants for caspase-3 interface mutants
Caspase-3 protein IC50 (nM) Ki (nM) Maximum inhibition (%)
WT 7.4+ −0.8 1.75+ −0.25 97+ −2
V266E 7.6+ −0.5 1.88+ −0.11 93+ −1.2
D3A,V266E 51.4+ −11.5 13.4+ −2.6 72+ −4.6
XIAP is a poor inhibitor of D3A,V266E
The high DEVD-ase activity of caspase-3 in transfected cell
lysates (Figure 3A) did not result in robust cell death (Figure 2A).
It has been shown that cell death involves a XIAP-dependent
threshold for activation of the effector caspases [28], where
XIAP is an endogenous potent inhibitor of activated caspase-3
[29]. Our results suggest that caspase-3 could be inhibited in the
cell by XIAP and that the mRIPA buffer (lysate preparation) and
subsequent dilution into caspase assay buffer released XIAP from
the active caspase-3, making measurement of the DEVD-ase
activity possible. XIAP binds and inhibits cleaved caspase-3
via a two-step binding mechanism involving interactions with
the active site and with the neo-epitope of the cleaved small
subunit in L2
  [17]. Our data suggest that V266E becomes
enzymatically active upon translation, without IL cleavage, so
one predicts that XIAP will be a less potent inhibitor of the
uncleaved procaspase D3A,V266E, since one binding site (L2
 )
may not be accessible to XIAP. In order to test this hypothesis,
we performed inhibition studies using recombinant WT and
V266E interface mutants (Figure 3B and Supplementary Figure
S6 at http://www.BiochemJ.org/bj/424/bj4240335add.htm). The
results show that XIAP efﬁciently inhibited WT and V266E,
presumably due to the fact that both proteins are cleaved (see
Figure 1B). The IC50 and the Ki values for the cleaved proteins
were similar (Table 1) and close to the values reported previously
[17]. In contrast, D3A,V266E was inhibited less efﬁciently by
XIAP (Figure 3B), displaying a Ki value of ∼ 8-fold higher in
comparison with WT (Table 1). The results also showed that
D3A,V266E could be inhibited by XIAP only up to ∼ 70% of its
maximumactivity,comparedwith∼ 97%forWT(Table1).This
information, translated to the intracellular environment where the
XIAP concentration does not exceed 50–70 nM [28], suggests
that the uncleaved mutant will be mostly uninhibited in the cell.
Because Asp
175 in the IL of procaspase-3 is a poor substrate for
cleavage by mature caspase-3 [30,31], we suggest that the V266E
mutants remain unprocessed in the cell at low concentrations,
effectively avoiding inhibition by XIAP. This explains the early
and robust cell death upon transfection with caspase-3 interface
mutants in comparison with WT. We have ensured that the active
sites of the interface mutants were equally competent for binding
other inhibitors that did not require interaction with the cleaved
form of caspase-3. For example, we show that the interface
mutants were inhibited by baculovirus p35 (Supplementary
Figure S6C) similarly to wild-type caspase-3. Furthermore,
we performed co-transfection experiments with plasmids
encoding the interface mutants and XIAP (Supplementary Figure
S7 at http://www.BiochemJ.org/bj/424/bj4240335add.htm). We
observedthatXIAPinhibitedcelldeathonlywhenpresentinlarge
excess compared with the caspase plasmid (>5:1 XIAP/caspase).
Our results are consistent with a low concentration of activated
procaspase-3 carrying out apoptosis. This assertion is consistent
with concentrations of active caspase-3 determined by molecular
simulation (1 nM) in the absence of XIAP and proteasome
degradation [32].
The X-ray crystal structure of V266E
In order to examine structural changes caused by the replacement
of Val
266, we crystallized and determined the structure of cleaved
V266E to 1.63 Å (Supplementary Table S1). The motivation for
replacing Val
266 with a glutamate residue was prompted by the
hydrophilic dimer interface of caspase-1, which contains Glu
390
(equivalent to Val
266 in caspase-3) and Arg
391.G l u
390 forms a
salt bridge with Arg
286 (Arg
164 in caspase-3), which is on L2,
neutralizes the positive charge from that residue and appears to
stabilize the active site.
Although the results show that the structure of V266E is very
similar to that of WT (PDB code 2J30), with an overall RMSD
(root mean square deviation) of 0.14 Å, two regions of the protein
are different. Changes in one or both regions presumably result in
the 3–4-fold lower enzyme activity. The ﬁrst is derived from the
IL, which in the uncleaved procaspase-3 is made of residues 169–
190.UponcleavageatAsp
175 duringmaturation,residues169–175
form L2 in the active site of one heterodimer and residues 176–
190 reach across to the other heterodimer to form the active site
L2
 .L 2
  is partially disordered in V266E, where we observe little
ornoelectrondensityforaminoacids176–185.Thisisincontrast
withthestructureofWT,wherethedisorderisfromresidues176–
179. In WT, several residues in L2
  form a H-bonding network
through water molecules with the P4 aspartate of the substrate
(Figure4A)[22],andtheremovaloftheseinteractionswasshown
to decrease activity [33]. In V266E, we observe electron density
startingwithLys
186.Importantly,His
185  inWTformstwoH-bonds
with Thr
245 at the C-terminus of helix 5. The contacts across the
interface anchor the base of L4 with L2
 , and these interactions
are not observed in the mutant. Disruption of contacts at
the C-terminus of helix 5 was shown previously to decrease the
activity of procaspase-3 [34].
Secondly,thedimerinterfaceofV266Ehasfeaturesincommon
with wild-type caspase-3 and with caspase-1, although Glu
266 in
the caspase-3 variant utilizes a different rotamer than does Glu
390
in caspase-1. In this case, Glu
266 interacts with Arg
164 through a
conserved water molecule (see Supplementary online data) rather
than through direct interactions as observed in caspase-1 (Figures
4B and 4C). Interestingly, when Glu
390 is replaced with an aspart-
ateresidueincaspase-1,thesaltbridgewithArg
286 ispreservedbut
is mediated by a water molecule [9]. In WT, the positive charge of
Arg
164 is neutralized by Glu
124, and these contacts are maintained
in the mutant (Figure 4B). When the structure is superimposed
with that of caspase-1, one ﬁnds that only one of the two active
sites aligns well (Figure 4C). When we modelled V266E with the
samerotamerasthatofcaspase-1,wefoundstericclashesbetween
Glu
266 and Glu
266 , across the dimer interface, and between Glu
266
and Tyr
197, on the adjacent β-strand (Figure 4D). This issue is al-
leviated in caspase-1 because of the presence of an insertion in β-
strand8,Arg
391,whichallowsGlu
390 toadoptarotamerthatmoves
the carboxylate closer to Arg
286 so that the two side chains are
withinH-bondingdistance(2.8Å),andbecauseacysteineresidue
(Cys
331) is present at the position equivalent to Tyr
197 in WT. So,
therotameradoptedforGlu
266 inthecaspase-3mutantseemstobe
somewhat of a compromise between avoiding steric clashes with
neighbouring amino acids and optimizing favourable interactions
with neighbouring residues and nearby water molecules.
Models of (in)active procaspase-3
Our previous biochemical data for D3A,V266E [11], as well
as that provided in the present study, show that the V266E
mutation effectively shifts the zymogen to an active conformer.
Currentlytherearenostructuresforprocaspase-3,sowegenerated
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Figure 4 V266E changes the dimer interface
(A) Interactions in L2  (cyan) with L4 (brown) and the P4-binding site of WT. Inset: N-termini of L2  for V266E begins at Lys186.( B) Dimer interface of WT (upper panel) demonstrating neutralization
of the positive charge of Arg164 and six conserved water molecules (see Supplementary online data), and dimer interface of V266E (lower panel). Contacts between Glu124 and Arg164 are maintained
inV266E,buttwowatermoleculesareremovedandtwoaredisplacedbythecarboxylateofGlu266.(C)ComparisonofthedimerinterfaceofV266E(grey)withthatofcaspase-1(yellow).Therotamer
at Glu390 in caspase-1 allows closer contact with the active site arginine. (D) V266E modelled using the rotamer found in caspase-1 demonstrates intra- and inter-subunit steric clashes with Tyr197
and Glu266 
.
homology models of the putative active and inactive zymogen in
order to examine the conformational switch. Owing to their high
sequence identity, we modelled inactive WT after procaspase-
7 [35,36], and energy minimized the structures as described in
the Experimental section (and the Supplementary online data) to
assure that our ﬁnal model is energetically feasible. We ﬁnd that,
similartoprocaspase-7,theactivesitesinourmodeloftheinactive
zymogen are disorganized and the IL occupies the central cavity.
Therearetwomonomers,representedbychainsAandB,forming
a complete dimer in the asymmetric unit of the procaspase-7
X-ray crystal structure. Our model of the inactive procaspase-3 is
similar to the entire dimer. Although the IL from chain A (IL-A)
in the procaspase-7 template mostly remains exposed to solvent,
a large portion of IL-B is buried in the interface, making contacts
withseveralinterfaceresiduesandshieldingthehydrophobiccore
from water (Figure 5A).
An examination of the model for inactive procaspase-3 shows
twofeaturesoftheproteinthatmaybeinvolvedinmaintainingthe
inactiveconformer.First,thedimerisasymmetricduetothebind-
ingofresiduesVal
178–Glu
190 fromIL-Bintheinterface.Asaresult
of the binding of IL-B, only residues His
185–Glu
190 from IL-A are
observed near the interface, and these residues mostly interact
with active site B. The asymmetric binding of the two ILs leads
to inhibition of the two active sites (from chains A and B) in two
complementary manners. For active site A, residues Cys
184–Val
189
from IL-B prevent insertion of active site loop 3 (chain A) into
the dimer interface (Figure 5B). Cys
184 and Val
189 (IL-B) in the in-
active procaspase-3 reside in the region occupied by Pro
201 (chain
A) in the active caspase-3. A similar sequence in caspase-7 was
referredtoasthe‘blockingsegment’becausetheresiduesprevent
formation of the substrate-binding pocket [35]. In addition, steric
clashes between the side chain of His
185 (IL-B) and the backbone
atoms of Gly
202 (L3) and Arg
164 (L2) (chain A) probably prevent
rotation of L2 from chain A into the active conformation, where
the side chain of Arg
164 rotates into the dimer interface to
intercalate between Pro
201 and Tyr
197, and the catalytic Cys
163
rotates into the P1 site (see Figure 5B, grey model). Similar
stericconstraintsareobservedinprocaspase-7(Figure5B,yellow
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.342 J. Walters and others
Figure 5 Homology models of (in)active procaspase-3
(A) Model of inactive procaspase-3 demonstrating binding of the IL (cyan) in the dimer interface, preventing organization of the active site loops. Colour code is the same as that used in Figure 1(B).
Note that L2 and L2  are covalently connected in the IL. (B) Superposition of inactive procaspase-3 (green residues) and of procaspase-7 (yellow) shows the blocking segment of IL-B, residues
184 –189  (procaspase-3 numbering), prevents insertion of active site loop 3 from monomer A. For clarity, only one residue from the blocking segment of procaspase-7 is shown (semi-transparent
sticks, Tyr211), whereas all of the residues of the blocking segment of procaspase-3 are highlighted (green). Upon cleavage of the IL, L2 , where the blocking segment resides, rotates ∼ 180◦ and
vacates the interface. Subsequently, a portion of the substrate-binding loop is permitted to insert in the interface. Arg164,T y r 197 and Pro201 engage in a stacking interaction (shown as the white
residues)onceL3insertsintheinterface.Insertionofthesubstrate-bindingloopispermittedintheactiveprocaspase-3(blueribbon)astheblockingsegmentliftsoutoftheinterfaceuponactivation
(blue residues). (C) Superposition of procaspase-7 (yellow) and of inactive procaspase-3 (green) reveals a blocking segment involving residues 179 –180  (caspase-3 numbering) of IL-B and
Val189 of IL-A, preventing insertion of L3 in the active site of monomer B. L3 (white ribbon, WT) cannot insert into the interface until the blocking segment (green, inactive procaspase-3; yellow,
procaspase-7) vacates the interface.
model). In the active procaspase-3, as well as upon cleavage of
the IL to yield caspase-3, removal of the blocking segment of IL-
B from the interface allows Pro
201 from chain A to move ∼ 6Å
into the active conformation, thus forming the substrate-binding
pocket for active site A. For active site B, a blocking segment
also prevents insertion of Pro
201 and the substrate-binding pocket,
but the interactions differ due to the asymmetric nature of the
inactive procaspase-3 dimer (Figure 5C). In this case, Val
189 (IL-
A) resides in the region occupied by Pro
201 (chain B) in the active
caspase-3, so Val
189 behaves similarly for both ILs. However, the
remainder of the blocking segment is comprised of the backbone
atoms of residues 179–182 from IL-B, which also reside in the
region occupied by Pro
201-Tyr
203 of the active caspase-3. Thus,
although the mechanisms differ somewhat for each active site,
thesubstrate-bindingloopsofbothactivesitesarepreventedfrom
inserting into the interface because the interface is occupied by
segments of IL-A and IL-B.
In addition to the blocking segments, a cluster of hydrophobic
amino acid residues centred about Val
266 appears to stabilize the
inactive conformer (Figure 6A), and a substitution of a glutamate
residue for Val
266 in the model of the inactive procaspase-3
suggests a mechanism for activation resulting from the mutation.
The hydrophobic cluster is comprised of seven residues: Met
182 ,
from IL-B, and Ile
187,I l e
187 ,V a l
189,V a l
189 ,V a l
266,a n dV a l
266  from
both monomers (Figure 6A). On the basis of this analysis, we
suggest that V266E activates the procaspase by disrupting the hy-
drophobic cluster and introducing steric clashes with Met
182  and
Ile
187  (Figure 6B), essentially expelling the IL from the dimer in-
terface:theﬁrstandmostimportantstepinactivation.Becausethe
glutamate side chain is approx. 2.5 Å longer than that of valine,
the IL is prevented from rebinding in the interface after its
release, and the protein conformation shifts to the active state.
It is important to note that the conformational shift occurs
without cleavage of the polypeptide chain at Asp
175.I nt h e
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Figure 6 V266E expels the IL from the interface
(A) Hydrophobic cluster in the inactive procaspase-3 centred about Val266. Residues in the
IL (cyan) of both monomers contribute to the cluster. (B) Because the glutamate side chain
is longer than that of valine, the V266E mutation probably disrupts the hydrophobic cluster,
preventing the IL from binding in the interface. (C) Comparison of the IL in the inactive and
active procaspase-3. H-bonds contributed by the loop bundle, and centred about Asp169,a r e
critical to active site stabilization. These contacts form only in the active conformer.
active conformer, both ILs occupy a region above the central
cavity, but have very few stabilizing contacts with the protease
domain (Figure 6C). Ramachandran plots show that the backbone
torsion angles are satisfactory (Supplementary Table S1), and
energy minimization was performed in CHARMm [37] to
alleviate energetically unfavourable conformations within the
protein (see Supplementary Experimental section at http://www.
BiochemJ.org/bj/424/bj4240335add.htm). Whether or not the
conformational details are correct, the most important revelation
obtained from our model of the active procaspase-3 (Figure 6C)
is that the IL is indeed long enough to allow formation of the loop
bundle at both active sites (contacts between Asp
169 and Val
189 ).
Similar to caspase-7, removal of the blocking segment from
the central cavity allows L3 to move into the dimer interface,
Arg
164 to rotate out of the substrate-binding pocket and into
the interface, and the catalytic groups to move into their active
positionssothattheactivesiteisorganizedsimilarlytothemature
caspase-3. Because L2 and L2
  remain covalently connected
in the IL, however, putative stabilizing interactions provided
by L2
  with the P4 aspartate of the substrate, described above,
are not possible in the procaspase. Supplementary Movie S2
(at http://www.BiochemJ.org/bj/424/0335/bj4240335add.htm)
shows the conformational switch between inactive and active
procaspase-3.
DISCUSSION
We show that the variant (pro)caspase-3 kills mammalian cells
rapidly compared with wild-type caspase-3. D3A,V266E is active
in the cell upon translation, and before processing at Asp
175,a n d
cleaves substrates similarly to the mature caspase. These features
are important for two reasons. First, endogenous procaspase-3
is a poor substrate for D3A,V266E, so cell death occurs due
to the activity of the procaspase variant on cellular substrates
rather than its activation of endogenous procaspase-3. In support
of this conclusion, we showed that MCF-7 cells, which lack
procaspase-3, undergo apoptosis when transfected with
D3A,V266E. Secondly, inhibition of the mutant by XIAP is weak
because the procaspase is not processed. In this case, the neo-
epitopeattheN-terminusofL2
 ,whichservesasasecondbinding
region for XIAP, remains sequestered in the procaspase.
Thelowthresholdofactivatedprocaspase-3ismuchlowerthan
the total cellular concentration of caspase-3, which is ∼ 100 nM
inapoptoticJurkat[4]andHEK-293cells[30].Theconcentration
ofthezymogenappearstobehigherthanthatofmaturecaspase-3
[38], although HeLa cells are estimated to contain approx.
120 nM procaspase-3 [28]. Under normal cellular conditions,
XIAPconcentrationsof50–60 nM[28]aresufﬁcienttoinhibitthe
small amount of activated caspase-3 and to target the protein for
degradation by the proteasome [39]. The induction of apoptosis
leads to massive activation of endogenous procaspase-3, which
overwhelms the control system and results in rapid cell death
[32]. Because XIAP does not efﬁciently inhibit D3A,V266E, a
low concentration of the pseudo-activated procaspase is sufﬁcient
for rapid cell death.
The interface mutation has little effect on the structure of the
mature caspase, but it appears to have a larger effect on that of
the procaspase. Our structural data show that L2
  is disordered
in V266E, and conserved water molecules are displaced at the
interface. Atpresent,itisnotclearhowamutationintheinterface
affects ordering of L2
 , since the regions that are affected are
>25 Å from the site of the mutation. Although residues in
L2
  H-bond with the P4 carboxylate of the substrate, removal
of those interactions do not signiﬁcantly affect the enzymatic
reaction. Val
266 resides at the centre of β-strand 8 in a water-
ﬁlled cavity, with the closest water molecules approx. 3.5 Å
from the hydrophobic side chains, well within van der Waals
contacts.AsdescribedbyWellsandco-workers,thisregionofthe
interface encompasses a site for binding of allosteric inhibitors,
which prevent active site formation, in general, by preventing the
insertion of the substrate-binding loop (L3) into the active site
cavity [10]. This is important because part of L3 extends into the
dimer interface and forms new contacts with residues in L2 in
addition to forming the base of the substrate-binding pocket. The
allosteric binding pocket is occluded in the procaspase due to the
positioning of the IL in the interface, and the ‘blocking segment’
of the IL prevents insertion of L3 into the active site. Our results
from the present study suggest that the inhibition is alleviated in
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D3A,V266E so that the IL is removed from the allosteric site,
allowing the active site loops to organize. Thus the allosteric site
linkedtoinhibitionoftheactivecaspasealsostabilizestheinactive
procaspase.
Theinactiveconformerappearstobestabilizedbyhydrophobic
and charge–charge interactions across the dimer interface, and
these stabilizing contacts are disrupted in the active conformer.
Uponremovalfromtheinterface-bindingsite,theILmovesacross
the surface of the protein to form the critical contacts contributed
by Asp
169, and the active conformer is stabilized primarily by
backbone H-bonds between the two ILs and those that form at
Asp
169. Stabilizing interactions in the mature caspase, contributed
byL2,L2
 ,L3andL4,areunabletoformintheactiveprocaspase.
Thelackofthesestabilizinginteractionsmayexplain,inpart,why
the inactive procaspase-3 is favoured.
Learning to selectively manipulate the level of apoptosis is
expected to lead to therapeutic strategies for a number of diseases
in which the dysregulation of apoptosis is a common factor.
Cancer cells, for example, typically have gained the ability to
circumvent apoptosis, so the proteins in the apoptotic cascades
have become ideal targets for cancer therapy [40–42]. We
suggest that directly targeting procaspase-3 could lead to more
effective therapy and lower drug resistance, since effector
caspases are the terminal proteases in the cell death programme.
Our results suggest that small molecules could bind to the dimer
interface of the zymogen and effectively mimic the effects of the
V266E mutation by releasing the IL from the allosteric site in the
interface. One advantage of this strategy, as shown in the present
study, is that the activation of endogenous procaspase-3 could
occur without cleavage at Asp
175 and may circumvent inhibition
by XIAP. Thus, compounds that induce a conformational change
in the zymogen, as does the V266E mutation, may show
great potential in drug design strategies. Modulation of caspase
inactivation from the dimer interface has been proposed before
[10], but we are the ﬁrst to show that the reverse mechanism,
activation, is possible by manipulating the dimer interface.
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The interface mutants do not affect oligomerization
Although the V266E mutation does not change the oligomeric
properties of caspase-3 at higher protein concentrations
(micromolar range) [1], we examined whether the mutation
weakens the dimer interface at lower protein concentrations by
performing dilution experiments coupled with enzyme activity
measurements (see Figure S1). The data follow a unimolecular
mechanism, suggesting that, at least in the presence of
the substrate, the caspase-3 mutants were stable dimers in the
picomolar range of protein concentration.
The interface mutants kill cells independently of endogenous
caspase-3
Because the substrate speciﬁcity is the same for the V266E
variants and WT (see Figure 1D in the main text), it is likely
that the mutants cleave the same substrates as caspase-3 during
apoptosis. Alternatively, it is possible that the interface mutants
activate the endogenous caspase-3, which then ampliﬁes the
downstream proteolytic events, although this is unlikely given
thatprocaspase-3istypicallyapoorsubstrateforactivecaspase-3
[2]. To examine the latter possibility, we transfected MCF7 cells,
which lack endogenous caspase-3 [3], with plasmids containing
the interface mutants, and we measured apoptosis by Annexin V
staining (see Figure S4A). Although the transfection efﬁciency
waslowerthaninthecaseofHEK-293Acells(∼ 35%compared
with∼ 60%respectively),thepatternofcelldeathobservedinthe
HEK-293A cells (see Figure 2A in the main text) was reproduced
intheMCF7cells(seeFigureS4A).OneshouldnotethatBax,the
positive control, was less toxic in MCF7 cells than were the inter-
face mutants due to the lack of endogenous caspase-3, the main
effector caspase. In all cases, the number of apoptotic cells
diminished in the presence of the caspase inhibitor Z-VAD-FMK.
Similarly, recombinant V266E cleaved caspase substrates in
the absence of caspase-3 when added to crude cellular extracts.
We examined hypotonic lysates from Jurkat cells that were
immunodepleted of the endogenous caspase-3 and reconstituted
with recombinant caspase-3 proteins. The lysates were analysed
by Western blot for cleavage of ICAD (see Figure S4B). We
observed that ICAD was cleaved efﬁciently by the active WT and
V266Eproteins,anditremainedunprocesseduponadditionofthe
less active procaspase-3. The cleavage of ICAD was judged by
the disappearance of the full-length protein for which the anti-
bodies were developed. Lysate prepared from cells treated with
Z-VAD-FMK showed no DEVD-ase activity (results not shown).
Conserved water molecules in the dimer interface
On one side of the interface, α-helices 5 and 5
  border β-strands
8a n d8
 , whereas the opposite face has a water-ﬁlled cavity
(see [4] for review). Moreover, several of the water molecules
found in the central cavity are conserved. We examined over
5000 crystallographic water molecules in 20 caspase-3 structures
with a resolution of 2.5Å or better, including proteins from
our own studies as well as those deposited in the PDB. We
considered water molecules that were within 1.4Å of one another
to be conserved, using a previously published method [4a].
The structures included in our conserved water analysis were
obtained from crystals with symmetry of various space groups
formed under different crystallization conditions and differing
in the number of molecules per asymmetric unit. Overall, the
analysis identiﬁed several conserved water molecules throughout
the structure of caspase-3, but we focus in the present study on
six conserved hydration sites in the dimer interface, which are
found in a pseudo-planar arrangement approx. 3.8Å above the
Val
266/Val
266  side chains (see Figure 4B of the main text).
In WT, Wat219 (where Wat is a water molecule) and Wat219
 
H-bondwiththehydroxygroupsofTyr
197 andTyr
197  respectively.
Bothofthesewatermoleculesalsointeractwithfourcentralcryst-
allographicwatermoleculestoprovideaH-bondingnetworkbrid-
gingthetwoactivesites.Wat192andWat192
  inthisnetworkalso
H-bond to Arg
164 and Arg
164  respectively. The water network is
disrupted in V266E, where Wat219 and Wat219
  are removed,
andthefourcentralwatermoleculesmovetopreventclasheswith
Glu
266 (Figure 4B). Interestingly, the carboxylates of Glu
266 and
Glu
266  displace Wat108 and Wat108
  respectively, and maintain
the planar contacts with Wat192 and Wat192
 . Overall, this
arrangementpreservestheH-bondingnetworkbetweenArg
164 and
Arg
164 , but removes H-bonds contributed by Tyr
197 and Tyr
197 .
EXPERIMENTAL
Positional scanning libraries
In the ﬁrst step, Fmoc (ﬂuoroen-9-ylmethoxycarbonyl)-ACC
ﬂuorophorewascoupledtotheRinkAmideResin(Novabiochem)
using a procedure described previously [5]. The Fmoc protecting
group was removed using 20% piperidine in DMF (dimethyl-
formamide). Coupling of the Fmoc-Asp(O-tBut)-COOH was
carried out in DMF using HATU as the coupling reagent and
in the presence of the 2,4,6-collidine base for 24 h at room
temperature. This step was repeated twice. The unreacted ACC
was acetylated as described previously [5]. The Fmoc protecting
1 Current address: Division of Medicinal Chemistry and Microbiology, Faculty of Chemistry, Wroclaw University of Technology, Wybrzeze Wyspianskiego
27, 50-370 Wroclaw, Poland
2 To whom correspondence should be addressed (email clay_clark@ncsu.edu).
The atomic co-ordinates and structure factors for caspase-3(V266E) have been deposited in the PDB under accession code 3ITN.
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Figure S1 Dilution studies of the V266E interface mutants
Theindicatedcaspase-3proteinsweredilutedinstandardassaybufferatconcentrationsbetween
0.15and10nMandincubatedfor15minat37 ◦C.Theenzymaticactivitywasdeterminedagainst
100μM Ac-DEVD-AFC.
group was removed using 20% piperidine in DMF and, after
washing with DMF, dichloromethane, THF (tetrahydrofolate)
and methanol, the resin was dried in vacuum. The resin was
distributed in 75 mg portions into 57 wells of a 96-deep-well
plate (semi-automatic FlexChem synthesizer). Standard peptide
synthesis was used to prepare the libraries. The amino acid or
mixture of amino acids, HOBt and DICI were preincubated for
4 min and added to the appropriate wells and agitated for 3 h
along with 30 min Fmoc decouplings in 20% piperidine in DMF.
The variable amino acid mixtures were prepared as an isokinetic
mixture with 19 amino acids (all amino acids omitting cysteine
and methionine due to the oxidation problems; norleucine was
used to mimic methionine). The N-termini of the tetrapeptides
were capped with acetate (Ac2Oa n dD I E Ai nD M F )f o r2h .
The resin was washed with DMF, dichloromethane, THF and
methanol, and the resin was dried in vacuum for 24 h. The
cleavage of the substrates was carried out for 1.5 h at room
temperature using the mixture of 92.5% TFA (triﬂuoroacetic
acid), 2.5% water, 2.5% tri-isopropyl silane and 2.5% phenol
(1.5 ml per well). After cleavage, TFA was removed and the
substrates were precipitated for 10 min at 0 ◦C using t-butyl-
methylether(12 ml)andcentrifuged.Thisstepwasrepeatedonce.
Subsequently,allACCsubstratesweredissolvedinwater/dioxane
(1:1, v/v) and freeze-dried for 48 h. Finally, all individual
substrates were dissolved as stock solutions at concentration of
50 mM in biological purity DMSO and stored frozen.
RT–PCR
HEK-293A cells, transfected with caspase-3 mutants and in the
presence of 100 μM ZVAD-FMK, were harvested and lysed in
TRizol® reagent (Invitrogen). The total RNA was extracted using
TRizol® as recommended by the manufacturer’s instructions and
resuspended in 50 μl of DEPC-treated water. Contaminating
genomic/plasmidial DNA was removed from the total RNA
solution by using the DNase free kit (Ambion). To prepare the
ﬁrst strand cDNA, ∼1 μg of (DNA-free) RNA was primed with
oligo(dT) and subjected to RT in 20 μl ﬁnal volume by using
the SuperScriptIII kit from Invitrogen. Control reactions did not
include the reverse transcriptase enzyme in the reaction mixture.
All cDNA samples (∼200 ng) were ampliﬁed by PCR using
either caspase-3-speciﬁc primers (forward: caspase-3 internal
primer; reverse: FLAG-tag primer) or primers designed to
amplify a housekeeping gene such as α-tubulin. Samples were
r u ni n0 . 8 % agarose gel and stained with ethidium bromide.
The DNA molecular ladder was from Invitrogen (DNA 1 kb
plus).
Cell lysate preparation
HEK-293A or MCF7 cells were harvested as described
above, washed with PBS, and the cell pellet was frozen
at −20◦C for a maximum of 3 days. Thawed cell pellets
were lysed on ice for 10 min with mRIPA buffer [modiﬁed
radioimmunoprecipitation buffer; 10 mM Tris/HCl, pH 7.4,
150 mM NaCl, 1% (v/v) Nonidet P40, 0.5% deoxycholate,
Figure S2 RT–PCR reactions of DNA-free RNA isolated from transfected HEK-293A cells
The following FLAG-tagged constructs were used: 1, vector control; 2, caspase-3 (WT); 3, procaspase-3(D3A); 4, caspase-3(V266E); 5, procaspase-3(D3A,V266E). The PCR reactions used speciﬁc
primers for caspase-3–FLAG and α-tubulin, depicted at the bottom of each panel. To rule out the possibility of plasmidial/genomic DNA contamination, control reactions (PCR) used RNA samples
subjected to RT reactions in the absence of the reverse transcriptase.
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0.1% SDS and 5 mM EDTA] containing the following protease
inhibitors: 50 μM DCI (dichloroisocoumain), 50 μM leupeptin,
50 μMM G 1 3 2a n d1 0 μME - 6 4 .L y s a t e sw e r ec l a r i ﬁ e db y
centrifugationat15000 gfor15 min.Forpreparationofhypotonic
Jurkat lysates, cells were treated as described previously
[6]. Jurkat lysates were immunodepleted for caspase-3 by
incubation with caspase-3 antibodies diluted 1:100 (BD clone
19) overnight at 4◦C, followed by the addition of Protein
A/G beads for 2 h [7]. Depleted Jurkat cell lysates were
reconstituted with recombinant caspase-3 mutants (25 nM ﬁnal
concentration) and incubated at 37◦C to allow caspase substrate
processing. The lysates were balanced for protein content before
immunoblotting.
Caspase assays
The protein concentrations in the cell lysates were determined
using the Bio-Rad DC protein assay, and the lysates were
normalized for protein content. To determine the activity of
the executioner caspases, cell lysates were diluted 1:5 in
caspase assay buffer [10 mM Pipes, pH 7.4, 150 mM NaCl,
0.1% CHAPS, 10% (w/v) sucrose and 10 mM DTT], incubated
for 15 min at 37◦C, and then the rate of hydrolysis of
ﬂuorogenic substrate (Ac-DEVD-AFC, 100 μM) was measured.
For inhibition studies using XIAP, the recombinant caspase-3
Figure S3 Inactive V266E variants no longer support apoptosis
(A) Western blots (upper panels) of cellular lysates from cells transfected with inactive variants
of V266E mutants (lower panel). Protein expression and activation was assessed by antibodies
against the FLAG tag, for detection of the transfected constructs, or cleaved PARP. Hsp90 panel
representsaloadingcontrol;*non-speciﬁcprotein.(B)Westernblotsofthecellularlysatesfrom
Figure 2(A) against anti-full-length PARP (nuclear extract) or cleaved PARP (cytosolic extract).
proteins (300–600 pM) were incubated for 30 min at
37 ◦C in modiﬁed caspase buffer [50 mM Hepes, pH 7.4,
100 mM NaCl, 10% (w/v) sucrose, 0.1% CHAPS, 20 mM
2-mercaptoethanol] with serial dilutions of XIAP (0–700 nM).
Residual activity was determined by the rate of hydrolysis
of Ac-DEVD-AFC (100 μM) with an f MAX Fluorescence Plate
Reader (Molecular Devices). The apparent inhibition constant
Ki,app or the IC50 was determined from the uninhibited rate (vo)
and inhibited rates (vi), by plotting the percentage of inhibition
(100×vi/v0) against inhibitor concentration [I]a ss h o w ni n
eqn 1:
100 ×
vi
v0
= b +
(100 − b) × Ki,app
Ki.app + [I]
(1)
where b is the baseline of inhibition at inﬁnite inhibitor
concentration. The value for baseline b approaches zero for
strict competitive inhibition and is more than 5–10 for mixed
Figure S4 Caspase-3 V266E mutants kill cells independently of the
presence of endogenous caspase-3
(A)MCF7cells,whichlackprocaspase-3,weretransfectedwith1μgoftotalDNA,asdescribed
inthelegendforFigure2ofthemaintext,and24hlaterthecellswerequantiﬁedbyFACSforAn-
nexinV-positivecells.Thevaluesrepresentthemeans+ −S.D.forthreeindependentexperiments.
(B) Hypotonic Jurkat lysates were immuno-depleted of endogenous caspase-3 (Casp-3
Depleted) and reconstituted with recombinant caspase-3. After incubation at 37 ◦C, cleavage of
ICAD was detected by immunobloting for full-length ICAD.
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inhibition. From the Michaelis–Menten constant, KM, of each
caspase mutant for the substrate Ac-DEVD-AFC and substrate
concentration [S], the true Ki of inhibition was calculated using
eqn 2:
Ki =
Ki,app
1 +
S
KM
(2)
For inhibition studies using p35, the experiments were carried out
as above, except that the concentration of caspase-3 was 2 nM
and that of p35 varied between 0 and 12 nM.
Figure S5 Relative DEVD-ase activity
(A) DEVD-ase activity in lysates prepared from cells transfected with WT or V266E for the
indicated time periods. (B) DEVD-ase activity in culture medium from cells transfected with
caspase-3 mutants. Cultures grown in complete growth medium were centrifuged at 500 g to
remove the cells. Supernatant (25μl) was mixed with 2× assay buffer (25μl), incubated at
37 ◦C for 10min, and the DEVD-ase activity was measured as described in the Experimental
section. The activity was normalized to the volume of the cell culture (∼2.5ml), but not to the
amount of protein from the cell lysates (see Figure 3 of the main text). The y-axis values for
DEVD-ase activities generated by cell medium and the cell lysates (see Figure 3 of the main
text) are not comparable. RFU, relative ﬂuorescence units.
FigureS6 Co-expressionofXIAPwiththecaspase-3V266Emutantscannot
rescue cells from apoptosis
(A) HEK-293A cells were transfected with 2μg of total DNA (1μg of caspase DNA plus 1μg
XIAP DNA for co-transfections) and, after 24h, the cells were quantiﬁed for Annexin V staining.
We note that the values for V266E and D3A,V266E in the presence of XIAP are not signiﬁcantly
differentgiventheerrorlimitsforthisexperiment.(B)Westernblotanalysisofthesamplesfrom
(A) showsthat XIAP doesnotaccumulatein cells containingthe caspase-3 V266Emutants.(C)
Allcaspase-3mutants(2nM)wereefﬁcientlytitratedwiththeviralinhibitorp35atconcentrations
as low as those approaching the Ki,app for inhibition.
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Procaspase-3 homology models, energy minimization and
molecular dynamics
Models of both the inactive and active procaspase-3 proteins
were built as described below, and the program CHARMm
version 27 [8] was used for molecular dynamics simulations and
energy minimizations to assure that the ﬁnal models represent
energetically feasible structures.
The inactive procaspase-3 model was generated using the
alignment mode of the SWISS-MODEL protein structure homo-
logy modelling server [9]. The target sequence, procaspase-3,
was modelled using procaspase-7 (PDB code 1K88) as the
template sequence. φ and ψ angles were corrected manually
with COOT [10] so that all dihedral angles throughout the
entirestructure werewithin acceptedvaluesintheRamachandran
plot (see Table S1). The IL in molecule B of procaspase-7 is
mostly, but not completely, ordered, such that residues 167–
177 (procaspase-3 numbering) are not visible in the electron
Figure S7 Poor inhibition of caspase-3 interface mutants by XIAP
(A) Co-transfection of caspase-3(V266E) with XIAP at various DNA ratios. (B) Co-transfection
of caspase-3(D3A,V266E) with XIAP at various DNA ratios. Transfections were performed with
increasing amounts of caspase-3 vector in the presence of a constant amount of XIAP vector
(). The control in the absence of XIAP is shown as . Cells were quantiﬁed by FACS for
Annexin V staining 20h post-transfection.
density maps. It was therefore necessary to build the missing
residues in order to obtain the structure of the complete IL.
Given the degrees of freedom available for the missing residues
in the linker, we acknowledge that our initial model included
one of several possible conformations for the missing section.
The starting conformation is one in which each additional
residue was built to have   and ψ angles in optimal regions
in the Ramachandran plot, as monitored by the appropriate
function in the program COOT, although at the same time
connecting the two ends of the IL already present in the
model.
The model of active procaspase-3(V266E) was built with
the wild-type caspase-3 structure as the template (PDB code
2J30). This is appropriate due to the high levels of activity of
D3A,V266E. On the basis of our previous results [11], Asp
169 and
Val
189 were used as anchor points, and the IL was built manually
using COOT. φ and ψ angles were inspected manually during
the initial building of the IL, as was performed for the model of
the inactive protein. In this case, however, the side chains for the
built residues have substantial degrees of freedom and were given
common rotamers. The backbone was built over the interface in
order to connect the two ends of the IL in a way to form the loop
bundle of both active sites, as is observed in active caspase-3.
After the initial building of the two models, any strains or
unfavourable conformations were relieved using the CHARMm
potential energy function with the PARAM19 parameter set
for extended atom representation and an atom-based force
switching function applied to non-bonded interactions, with
the switch starting at 5Å and ending at 6Å. All energy
minimizationswereperformedusingagradienttolerancecutoffof
0.0001.
The initial models were placed in equilibrated 62Å cubes
of TIP3P [12] water molecules, and all atoms within 2.6Å
of any protein atom or crystallographic water molecule were
deleted on a group-wise basis. This resulted in a protein
solvated by 5417 and 5325 water molecules for the inactive
and active models respectively. All calculations were performed
with periodic boundary conditions. Bonds containing hydrogen
were constrained to their equilibrium bond lengths using the
SHAKEalgorithm[13].Energyminimizationwasachievedusing
a combined approach of 100 steps of steepest descent followed
by 1000 steps of conjugate gradient. Each model was then
subject to 10 ps of molecular dynamics simulations at 1000 K
with a representative structure saved every 1 ps during the
trajectory. The elevated temperature was for greater sampling of
conformational space.The leapfrog Verlet algorithm was usedfor
numerical integration of Newton’s equations of motion at 0.001
ps intervals. The ten structures saved during each trajectory were
energy minimized with 100 steps of steepest descent. The ILs in
the resulting ten models of the inactive procaspase-3 and active
procaspase-3 showed a main chain RMSD (root mean square
deviation)of0.308Åand0.244Årespectively,demonstratingthat
at least within the radius of convergence given by our simulation
conditions there is a single overall conformation of the IL in each
case.
Comparison of the ﬁnal model of inactive procaspase-3 with
the procaspase-7 template using the brute force alignment
in LSQMAN [14] resulted in an overall RMSD of 0.416Å,
demonstrating good agreement between the target structure and
the model. Similarly, the RMSD between our model of the active
procaspase-3(V266E) and the wild-type caspase-3 template is
0.226Å, excluding the L2
  residues, which must differ in the two
structuresduetoitsconnectivitytotherestoftheILinprocaspase-
3 and its positioning in the active site in the adjacent heterodimer
in the mature caspase-3 dimer.
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Table S1 Summary of data collection and reﬁnement statistics for caspase-3(V266E)
Space group I222
Unit cell a=69.224 A ˚
b=84.607 A ˚
c=96.171 A ˚
α =90◦
β =90◦
γ =90◦
Temperature (K) 100
Resolution (A ˚)1 . 6 3
Number of reﬂections 41720
Completeness (%) 99
Redundancy 3.0
Rsym (%)a 11.1
Average I/σ 17.8 (6.1)
Rwork (%)b 20.17
Rfree (%)c 23.54
RMSD for bond lengths (A ˚) 0.005
RMSD for bond angles (A ˚)1 . 2
Number of protein atoms 1939
Number of water molecules 297
Ramachandran statistics
WT V266E Procaspase-3 (inactive) Procaspase-3 (active)
In preferred regions 235 (96.7%) 233 (97.9%) 416 (88.1%) 452 (93.4%)
In allowed regions 5 (2.1%) 5 (2.1%) 47 (10%) 28 (5.8%)
Outliers 3 (1.2%) 0 (0%) 9 (1.9%) 4 (0.8%)
a Rsym =

|li− < l > |/

l
bRwork =

||F0|−|Fc||/

|F0,calculated by using 90 % of the reﬂections against which the model was reﬁned.
cR =

||F0 −|Fc||/

|F0|,calculated by using a test set consisting of 10 % of the total reﬂections, randomly selected from the original data set.
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